Head of Bayer LifeScience Center: Expect More JVs
This article was originally published in Scrip
The head of Bayer AG's new "breakthrough" R&D unit expects to form more joint ventures with cutting-edge biotechnology start-ups like the one announced with Switzerland-based CRISPR Therapeutics aimed at harnessing their technologies and linking them with Bayer's expertise.
You may also be interested in...
As new scientific breakthroughs are shaking the foundations of pharma and biotech R&D, In Vivo sat down with Bayer's Kemal Malik to hear how the German big pharma is responding to the challenges with its ground-breaking LEAPS program.
In the spirit of the BIO International Convention's partnering focus, Scrip covered a dealmaker survey and spoke to Bayer about some of its business development priorities on day two of the annual convention. We also report on a payer perspective, post-Brexit EMA rumors and investments in vaccines.
CRISPR Therapeutics says its IP position has been reinforced by the European Patent Office's aim to grant the University of California patent recognition covering CRISPR gene-editing for non-cellular and cellular use.